DRG2 and glioblastoma: From the survival analysis, we found that low expression of NOL3, DRG2, B3GAT3, FAM172A, CRELD1, AGFG2, TNIP1, RNF6, ERBB2, FOXO-P, and NDRG1 enhanced GBM patients’ survival and significantly decreased the hazard ratio.